Effectiveness of the combined evaluation of KLK3 genetics and free-to-total prostate specific antigen ratio for prostate cancer diagnosis

Journal of Urology

Volumn 188, Issue 4, 2012, Pages 1124-1130

  Zambon, Carlo Federico ^a   Prayer Galetti, Tommaso ^a   Basso, Daniela ^a   Padoan, Andrea ^a   Rossi, Elisa ^a   Secco, Silvia ^a   Pelloso, Michela ^a   Fogar, Paola ^a   Navaglia, Filippo ^a   Moz, Stefania ^a   Zattoni, Filiberto ^a   Plebani, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

3 oxo 5 alpha steroid 4 dehydrogenase; genetic; polymorphism; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

MEMBRANE PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KLK3; STEROID 5ALPHA REDUCTASE 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; COST CONTROL; DISEASE ASSOCIATION; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84866113641     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.06.030     Document Type: Article

References (26)

1. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310
2. F.H. Schröder, J. Hugosson, M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320
3. D. Ilic, D. O'Connor, S. Green Screening for prostate cancer: an updated Cochrane systematic review BJU Int 107 2011 882
4. H. Lilja, D. Ulmert, A.J. Vickers Prostate-specific antigen and prostate cancer: prediction, detection and monitoring Nat Rev Cancer 8 2008 268
5. A.W. Roddam, M.J. Duffy, F.C. Hamdy Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 48 2005 386
6. D. Basso, P. Fogar, M.G. Piva Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology 55 2000 710
7. G. Pilia, W.M. Chen, A. Scuteri Heritability of cardiovascular and personality traits in 6,148 Sardinians PLoS Genet 2 2006 e132
8. R.A. Eeles, Z. Kote-Jarai, G.G. Giles Multiple newly identified loci associated with prostate cancer susceptibility Nat Genet 40 2008 316
9. K.L. Penney, F.R. Schumacher, P. Kraft Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels Carcinogenesis 32 2011 853
10. H. Parikh, Z. Wang, K.A. Pettigrew Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels Hum Genet 129 2011 675
11. Z. Kote-Jarai, A. Amin AlOlama, D. Leongamornlert Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript Hum Genet 129 2011 687
12. J. Ahn, S.I. Berndt, S. Wacholder Variation in KLK genes, prostate-specific antigen and risk of prostate cancer Nat Genet 40 2008 1032
13. J. Xu, S.D. Isaacs, J. Sun Association of prostate cancer risk variants with clinicopathologic characteristics of the disease Clin Cancer Res 14 2008 5819
14. F. Wiklund, S.L. Zheng, J. Sun Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer Prostate 69 2009 419
15. S. Lindstrom, F. Schumacher, A. Siddiq Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers-results from BPC3 PLoS One 6 2011 e17142
16. S.D. Cramer, B.L. Chang, A. Rao Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels J Natl Cancer Inst 95 2003 1044
17. C. Ntais, A. Polycarpou, A. Tsatsoulis Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes Eur J Endocrinol 149 2003 469
18. N. Makridakis, R.K. Ross, M.C. Pike A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase Cancer Res 57 1997 1020
19. G. Schatzl, S. Madersbacher, A. Gsur Association of polymorphisms within androgen receptor, 5alpha-reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men Prostate 52 2002 130
20. J.K. Scariano, E. Treat, F. Alba The SRD5A2 V89L polymorphism is associated with severity of disease in men with early onset prostate cancer Prostate 68 2008 1798
21. E. Audet-Walsh, J. Bellemare, G. Nadeau SRD5A polymorphisms and biochemical failure after radical prostatectomy Eur Urol 60 2011 1226
22. R.J. Klein, C. Halldén, A.M. Cronin Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer Cancer Prev Res 3 2010 611
23. A. Heidenreich, J. Bellmunt, M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. European Association of Urology Eur Urol 59 2011 61
24. A.K. Kader, J. Sun, S.D. Isaacs Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients Prostate 69 2009 1195
25. R.S. Punglia, A.V. D'Amico, W.J. Catalona Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen N Engl J Med 349 2003 335
26. J. Gudmundsson, S. Besenbacher, P. Sulem Genetic correction of PSA values using sequence variants associated with PSA levels Sci Transl Med 2 2010 62ra92